VYNE shareholders approve reverse stock split; receives $5M deferred payment; redeems preferred

VYNE Therapeutics Inc.

Stockholders approved reverse stock split at ratio from 1:10 to 1:25; board to set effective date within one year.
Series A Preferred redeemed for $360,000 on Jan 17, 2023; Certificate of Elimination to be filed.
Received $5.0M deferred payment from Journey Medical per Asset Purchase Agreement; pro forma cash $35.9M as of Dec 31, 2022.

item 2.02 item 8.01 item 5.07 item 7.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

VYNE Therapeutics Inc. shareholders approved Adjournment Proposal at the 2023-01-12 meeting.

Outcome: passed
Meeting: 2023-01-12

Exact text from the filing

With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,029,283; votes “Against” were 3,693,414; votes abstaining or withheld were 423,246, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows: Votes For Votes Against Abstentions / Withheld 2,624,348,039 403,374,658 423,246 The Adjournment Proposal was approved.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

VYNE Therapeutics Inc. shareholders approved Reverse Stock Split Proposal at the 2023-01-12 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-01-12

Exact text from the filing

With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,230,441; votes “Against” were 3,711,239; votes abstaining or withheld were 204,263, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows: Votes For Votes Against Abstentions / Withheld 2,625,767,750 402,173,930 204,263 The Reverse Stock Split Proposal was approved.

View on SEC.gov

Browse all shareholder votes →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-003471

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.